Protein binding to akt2
CA 2508232 A1 · Owner: Astellas Pharma Inc. · Inventors: Ueda, Yoshitaka; Inabe, Kazunori; Endo, Yuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel polypeptide useful in screening an insulin resistance improving agent and a saccharometabolism improving agent; a polynucleotide encoding this polypeptide; an expression vector containing this polynucleotide; and cells transfected with this expression vector. The above-described polypeptide is a protein expressed in fat and the activity of Akt2 is lowered in adipocytes with the overexpression of this protein. A method of screening an insulin resistance improving agent and a saccharometabolism improving agent by using the above-described polypeptide; and a process for producing a composition for improving insulin resistance and improving saccharometabolism which contains a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.